☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
takeda
Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)
September 25, 2024
Takeda Reports the EC’s Approval of Adzynma to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
August 7, 2024
Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer
June 25, 2024
Takeda Reports Topline Data from P-III (SKYLINE and SKYWAY) Studies of Soticlestat for Dravet Syndrome (DS) and Lennox-Gastaut Syn...
June 18, 2024
Takeda Enters into an Option Agreement with Ascentage Pharma for Olverembatinib to Treat Chronic Myeloid Leukemia
June 17, 2024
Takeda’s ADAMTS13 Receives the CHMP’s Positive Opinion for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 31, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.